Endothelial cell biomarkers in critically ill COVID‐19 patients with encephalitis

Altmayer, Victor; Ziveri, Jason; Frère, Corinne; Salem, Joe‐Elie; Weiss, Nicolas; Cao, Albert; Marois, Clémence; Rohaut, Benjamin; Demeret, Sophie; Bourdoulous, Sandrine; Guennec, Loïc Le

doi:10.1111/jnc.15545

Cited by 16 publications

(14 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 110 111 112 113 This induces endothelial dysfunction that disrupts neurovascular units, leading to breakdown of the BBB. 110 114 115 116 117 118 Based on experience from SARS-CoV-1 infection and various theories, the involvement of the hypothalamopituitary axis has also been postulated in immune dysregulation. 119 120 …”

Section: Discussionmentioning

confidence: 99%

AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines—A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Background and Purpose Autoimmune encephalitis (AIE) following coronavirus disease 2019 (COVID-19) is an underexplored condition. This study aims to systematically review the clinico-investigational and pathophysiologic aspects of COVID-19 and its vaccines in association with AIE, and identify the factors predicting neurological severity and outcomes. Methods Relevant data sources were searched using appropriate search terms on January 15, 2022. Studies meeting the criteria for AIE having a temporal association with COVID-19 or its vaccines were included. Results Out of 1,894 citations, we included 61 articles comprising 88 cases: 71 of COVID-19-associated AIE, 3 of possible Bickerstaff encephalitis, and 14 of vaccine-associated AIE.There were 23 definite and 48 possible seronegative AIE cases. Anti-NMDAR (N-methyl-D-aspartate receptor; n =12, 16.9%) was the most common definite AIE. Males were more commonly affected (sex ratio=1.63) in the AIE subgroup. The neurological symptoms included alteredmental state ( n =53, 74.6%), movement disorders ( n =28, 39.4%), seizures ( n =24, 33.8%), behavioural ( n =25, 35.2%), and speech disturbances ( n =17, 23.9%). The median latency to AIE diagnosis was 14 days (interquartile range=4–22 days). Female sex and ICU admission had higherrisks of sequelae, with odds ratio (OR) of 2.925 (95% confidence interval [CI]=1.005–8.516)and 3.515 (95% CI=1.160–10.650), respectively. Good immunotherapy response was seen in42/48 (87.5%) and 13/13 (100%) of COVID-19-associated and vaccine-associated AIE patients, respectively. Sequelae were reported in 22/60 (36.7%) COVID-19 associated and 10/13 (76.9%) vaccine-associated cases. Conclusions The study has revealed diagnostic, therapeutic, and pathophysiological aspects of AIE associated with COVID-19 and its vaccines, and its differences from postinfectious AIE. Systematic review registration PROSPERO registration number CRD42021299215

show abstract

Section: Discussionmentioning

confidence: 99%

AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines—A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The reported findings discussed above (Altmayer et al, 2021) regarding the neurological complications associated with COVID‐19 warrant further investigations to decipher the mechanistic basis of CNS damage. This will facilitate the development of potential therapeutic strategies, thus reducing disease morbidity.…”

Section: Angptl4 As a Biomarker For Covid‐19‐associated Encephalitismentioning

confidence: 86%

Catching hold of COVID‐19‐related encephalitis by tracking ANGPTL4 signature in blood

Chakraborty

Basu

2021

Journal of Neurochemistry

View full text Add to dashboard Cite

Infection by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) in humans is characterized by a plethora of symptoms varying in intensity, such as non‐specific febrile illness, dry cough, dyspnea, hypoxemia to severe lung damage, and even death. In addition to pulmonary complications associated with coronavirus disease‐19 (COVID‐19), perturbations in the physiology of multiple other organ systems have been reported, resulting in multiorgan failure (MoF) that is frequently observed in severe COVID‐19 cases. Central nervous system (CNS) infection by SARS‐CoV‐2 is characterized by neurological impairments in patients with COVID‐19, with the development of encephalopathy at the severe end of the spectrum. While mechanistic investigations of SARS‐CoV‐2‐related encephalitis may reveal promising therapeutic candidates for reducing COVID‐19‐associated disease morbidity, the discovery of biomarkers capable of diagnosing and predicting prognosis in patients with encephalitis upon SARS‐CoV‐2 infection will afford significant value for the rapid detection of encephalitis and predicting disease outcomes. This will ultimately enable appropriate modifications of therapeutic regimens aimed at reducing disease morbidity and mortality. In this editorial, we highlight a study by Le Guennec and colleagues, entitled “Endothelial cell biomarkers in critically ill COVID‐19‐patients with encephalitis”, reporting the association of increased serum angiopoietin‐like 4 (ANGPTL4) abundance with COVID‐19‐related encephalitis. The study highlights ANGPTL4 as a potential molecular marker for this disease. These novel findings may catalyze developments in the field of COVID‐19‐associated encephalitis by facilitating accurate and rapid diagnosis of encephalitis and timely treatment initiation, thus improving patient outcomes by ameliorating disease burden.

show abstract

“…We are excited to see the quality and diversity of the work submitted and accepted for publication by the Journal of Neurochemistry . From molecular mechanisms in cultured cells (Agbaegbu Iweka et al, 2021; Bendahmane et al, 2020), neurochemical mechanisms in intact organisms (Abreu et al, 2021; Becker et al, 2021), new imaging and quantitative methodologies providing insight into neurochemical changes (Abdalla et al, 2020; Arber et al, 2021; Blank & Hopf, 2021; Dienel, 2021) and critical biomarkers in disease (Altmayer et al, 2021; Chakraborty & Basu, 2021; Chatterjee et al, 2021; Eden et al, 2021; Geula et al, 2021; Ginsberg et al, 2021; Glezer et al, 2021), the scope of the Journal of Neurochemistry has broadened to respond to the demands of our scientific community. Neurochemical mechanisms of disease are a popular topic covering neuropsychiatric and developmental disorders (Haase et al, 2021; Kozlowska et al, 2021; Liu & McNally, 2021; Nie et al, 2021; Nomura et al, 2021) and neurodegenerative diseases (Brosseron et al, 2021; Butler et al, 2021; Chatterjee et al, 2021; Korecka & Shaw, 2021; Sathe et al, 2021; Trinh et al, 2021; Yuede et al, 2021).…”

Section: Figurementioning

confidence: 99%

Editorial: Exciting developments in neurochemistry research and publishing

Lawrence

Prado

2022

Journal of Neurochemistry

View full text Add to dashboard Cite

In this editorial, we are happy to connect with our community to explain the changes introduced to the Journal of Neurochemistry over the last year and provide some insights into new developments and exciting opportunities.We anticipate these developments, which are strongly guided to increase transparency and support early career researchers, will increase the value of the Journal of Neurochemistry for the authors and readers. Ultimately, we hope to improve the author experience with the Journal of Neurochemistry and continue to be the leading venue for fast dissemination of exciting new research focusing on how molecules, cells and circuits regulate the nervous system in health and disease.

show abstract

Endothelial cell biomarkers in critically ill COVID‐19 patients with encephalitis

Cited by 16 publications

References 75 publications

AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines—A Systematic Review

AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines—A Systematic Review

Catching hold of COVID‐19‐related encephalitis by tracking ANGPTL4 signature in blood

Editorial: Exciting developments in neurochemistry research and publishing

Contact Info

Product

Resources

About